Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.0%

Neg 0% Neu 88% Pos 0%

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $26 price target.

Comments

No comments yet. Be the first!